ARRIVENT BIOPHARMA, INC. Investment Income, Net
ARRIVENT BIOPHARMA, INC. (AVBP) reported Investment Income, Net of $2.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. investment income, net for the quarter ending 2026-06-30 was $2.80M, a 25.81% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. investment income, net for the quarter ending 2026-03-31 was $2.79M, a 17.02% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. investment income, net for the quarter ending 2025-12-31 was $3.28M, a 6.74% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. investment income, net for the quarter ending 2025-09-30 was $3.34M, a 9.00% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. investment income, net for fiscal 2025 was $11.23M, a 18.77% decline from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. investment income, net for fiscal 2024 was $13.82M, a 162.89% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. investment income, net for fiscal 2023 was $5.26M.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.80M 10-Q · filed 2026-08-12 | $5.59M 10-Q · filed 2026-08-12 | $8.87M derived: sum of 3 quarters · filed 2026-08-12 | $12.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.79M 10-Q · filed 2026-05-11 | $6.07M derived: sum of 2 quarters · filed 2026-05-11 | $9.41M derived: sum of 3 quarters · filed 2026-05-11 | $11.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.62M derived: sum of 2 quarters · filed 2026-03-05 | $8.84M derived: sum of 3 quarters · filed 2026-08-12 | $11.23M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.34M 10-Q · filed 2025-11-10 | $5.56M derived: sum of 2 quarters · filed 2026-08-12 | $7.95M 10-Q · filed 2025-11-10 | $11.02M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.22M 10-Q · filed 2026-08-12 | $4.61M 10-Q · filed 2026-08-12 | $7.68M derived: sum of 3 quarters · filed 2026-08-12 | $11.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.38M 10-Q · filed 2026-05-11 | $5.46M derived: sum of 2 quarters · filed 2026-05-11 | $9.13M derived: sum of 3 quarters · filed 2026-05-11 | $12.95M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.74M derived: sum of 2 quarters · filed 2026-03-05 | $10.56M derived: sum of 3 quarters · filed 2026-03-05 | $13.82M 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.67M 10-Q · filed 2025-11-10 | $7.49M derived: sum of 2 quarters · filed 2025-11-10 | $10.75M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $3.82M 10-Q · filed 2025-08-11 | $7.08M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $3.26M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $5.26M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |